Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) were down 4.2% on Monday . The company traded as low as $1.73 and last traded at $1.73. Approximately 119,813 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 1,997,533 shares. The stock had previously closed at $1.80.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on PGEN shares. HC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Precigen in a research note on Thursday. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $7.00.
Read Our Latest Stock Analysis on Precigen
Precigen Trading Down 3.6 %
The firm has a market cap of $505.20 million, a price-to-earnings ratio of -3.15 and a beta of 1.58. The company has a 50 day moving average of $1.58 and a 200 day moving average of $1.14.
Institutional Trading of Precigen
Hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its stake in Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock worth $2,720,000 after buying an additional 29,253 shares during the period. LexAurum Advisors LLC raised its stake in Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock worth $775,000 after buying an additional 417,055 shares during the period. Iridian Asset Management LLC CT raised its stake in shares of Precigen by 38.8% in the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock valued at $5,871,000 after purchasing an additional 1,465,962 shares during the period. Geode Capital Management LLC raised its stake in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 149,829 shares during the period. Finally, Stifel Financial Corp raised its stake in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares during the period. Institutional investors and hedge funds own 33.51% of the company's stock.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Stories
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
